Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC13A5 | Q86YT5 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.47 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.46 |
| ▸ | SOX18 | P35713 | 1/20 | 0.45 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.43 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5144294 | 0.82 | ALDH1A1 (0.47) | SLC13A5HDAC1HDAC8FFAR1 | |
| SCHEMBL16595060 | 0.78 | SLC13A5 (0.62) | SLC13A5CYP1A2HDAC1HDAC8PDPK1 | |
| SCHEMBL22920703 | 0.77 | CYP1A2 (0.55) | SLC13A5CYP1A2HDAC1HDAC8CYP2A6 | |
| SCHEMBL10508659 | 0.74 | ALDH1A1 (0.47) | SLC13A5HDAC1HDAC8 | |
| SCHEMBL20067118 | 0.74 | CYP1A2 (0.50) | SLC13A5CYP1A2PDPK1CYP2A6CTSB | |
| SCHEMBL4610682 | 0.74 | CYP1A2 (0.50) | SLC13A5CYP1A2PDPK1CYP2A6FFAR1 | |
| SCHEMBL8298610 | 0.74 | SLC13A5 (0.51) | SLC13A5CYP1A2HDAC1HDAC8PDPK1 | |
| SCHEMBL11822095 | 0.74 | CYP1A2 (0.52) | SLC13A5CYP1A2CYP2A6SIGMAR1 | |
| SCHEMBL8939501 | 0.72 | CYP1A2 (0.62) | SLC13A5CYP1A2CYP2A6CTSBCTSS | |
| SCHEMBL29982408 | 0.72 | CYP1A2 (0.62) | SLC13A5CYP1A2CYP2A6CTSBCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1224164-B1 | HYDROXAMIC ACID DERIVATIVE AS INHIBITOR OF THE FORMATION OF SOLUBLE HUMAN CD23 | SMITHKLINE BEECHAM PLC (GB) | 2004-12-08 | — | — | EP | disclosed |
| EP-1089963-B1 | HYDROXAMIC ACID DERIVATIVES AS INHIBITORS OF THE PRODUCTION OF HUMAN CD23 AND OF THE TNF RELEASE | SMITHKLINE BEECHAM PLC (GB) | 2004-06-16 | — | — | EP | disclosed |
| US-6673965-B1 | AUTOIMMUNE DISEASE, INFLAMMATION, ALLERGY; IN-VIVO ABSORPTION BIOAVAILABILITY VIA THE ORAL ROUTE; DEPROTECTING, REACTING WITH HYDROXYLAMINE; N'-(4-(N-HYDROXYAMINO)-3S-ISOPROPOXY-2R-(2-NAPHTHYLMETHYL) SUCCINYL)-S-TERT-LEUCINE METHYLAMIDE | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-01-06 | — | — | US | disclosed |
| US-6458779-B1 | TREATMENT OF CONDITIONS ASSOCIATED WITH EXCESS PRODUCTION OF SOLUBLE CD23 (S-CD23) SUCH AS AUTOIMMUNE DISEASE AND ALLERGY. THE COMPOUNDS OF THE INVENTION ARE ALSO INHIBITORS OF THE RELEASE OF TUMOUR NECROSIS FACTOR (TNF). | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-10-01 | — | — | US | disclosed |
| EP-1089963-A1 | HYDROXAMIC ACID DERIVATIVES AS INHIBITORS OF THE PRODUCTION OF HUMAN CD23 AND OF THE TNF RELEASE | SMITHKLINE BEECHAM PLC (GB) | 2001-04-11 | — | — | EP | disclosed |
| WO-1999067201-A1 | HYDROXAMIC ACID DERIVATIVES AS INHIBITORS OF THE PRODUCTION OF HUMAN CD23 AND OF THE TNF RELEASE | SMITHKLINE BEECHAM PLC (GB) | 1999-12-29 | — | — | WO | disclosed |